Dasatinib (BMS-35482) potentiates the activity of gemcitabine and docetaxel in uterine leiomyosarcoma cell lines

Table 2 The combination index (CI) in uterine LMS cell lines

Cell Line	Drugs	Combination index (CI) at the IC ₅₀
SK-UT-1
	Gemcitabine:Docetaxel	0.59
	Gemcitabine + Docetaxel + Dasatinib	0.46
	Dasatinib- > Gemcitabine + Docetaxel	1.77
	Gemcitabine + Docetaxel- > Dasatinib	1.14
	Dasatinib + Gemcitabine- > Docetaxel	1.32
	Dasatinib + Docetaxel- > Gemcitabine	1.07
	Gemcitabine- > Docetaxel + Dasatinib	1.8
	Docetaxel- > Gemcitabine + Dasatinib	N/D
SK-UT-1B
	Gemcitabine:Docetaxel	1.36
	Gemcitabine + Docetaxel + Dasatinib	1.4
	Dasatinib- > Gemcitabine + Docetaxel	0.9
	Gemcitabine + Docetaxel- > Dasatinib	1.36
	Dasatinib + Gemcitabine- > Docetaxel	1.21
	Dasatinib + Docetaxel- > Gemcitabine	1.0
	Gemcitabine- > Docetaxel + Dasatinib	0.9
	Docetaxel- > Gemcitabine + Dasatinib	1.5

Combination index scale: CI <0.9 synergistic, CI = 0.9-1.1 additive, CI = 1.1-1.2 slight antagonism,
CI = 1.2-1.45 moderate antagonism, CI = 1.45-3.3 antagonism, CI = 3.3-10 strong antagonism.
N/D = not determined.

ISSN: 2053-6844